UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 387

Sortiert nach

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

Leukemia, 2021-01, Vol.35 (1), p.1-17

2021

Volltextzugriff (PDF)

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

The New England journal of medicine, 2012-03, Vol.366 (9), p.787-798

2012

Volltextzugriff (PDF)

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

The New England journal of medicine, 2021-03, Vol.384 (11), p.1028-1037

2021

Volltextzugriff (PDF)

From leeches to interferon: should cytoreduction be prescribed for all patients with polycythemia vera?

Leukemia, 2020-11, Vol.34 (11), p.2837-2839

2020

Volltextzugriff (PDF)

The renaissance of interferon therapy for the treatment of myeloid malignancies

Blood, 2011-05, Vol.117 (18), p.4706-4715

2011

Volltextzugriff (PDF)

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Leukemia, 2022-05, Vol.36 (5), p.1408-1411

2022

Volltextzugriff (PDF)

Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia

The New England journal of medicine, 2014-07, Vol.371 (2), p.188-189

2014

Volltextzugriff (PDF)

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Haematologica (Roma), 2015-09, Vol.100 (9), p.1139

2015

Volltextzugriff (PDF)

Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980

Journal of clinical oncology, 2011-10, Vol.29 (29), p.3907-3913

2011

Volltextzugriff (PDF)

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Journal of hematology and oncology, 2017-09, Vol.10 (1), p.156-6, Article 156

2017

Volltextzugriff (PDF)

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

Journal of clinical oncology, 2021-09, Vol.39 (26), p.2881-2892

2021

Volltextzugriff (PDF)

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Journal of clinical oncology, 2011-02, Vol.29 (6), p.761-770

2011

Volltextzugriff (PDF)

CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients

Haematologica (Roma), 2021-03, Vol.106 (3), p.863

2021

Volltextzugriff (PDF)

Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis

Blood, 2012-12, Vol.120 (25), p.4921-4928

2012

Volltextzugriff (PDF)

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review

Haematologica (Roma), 2019-08, Vol.104 (8), p.1580

2019

Volltextzugriff (PDF)

Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis

Blood, 2019-02, Vol.133 (8), p.790-794

2019

Volltextzugriff (PDF)

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

Blood, 2013-06, Vol.121 (23), p.4778-4781

2013

Volltextzugriff (PDF)

Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis

Blood cancer journal (New York), 2021-07, Vol.11 (7), p.135-135, Article 135

2021

Volltextzugriff (PDF)

Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study

Haematologica (Roma), 2018-01, Vol.103 (1), p.51

2018

Volltextzugriff (PDF)

Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups

Bone marrow transplantation (Basingstoke), 2021-08, Vol.56 (8), p.1888-1899

2021

Volltextzugriff (PDF)

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms

Haematologica (Roma), 2015-09, Vol.100 (9), p.1117

2015

Volltextzugriff (PDF)

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib

Haematologica (Roma), 2024-02, Vol.109 (2), p.676

2024

Volltextzugriff (PDF)

1 – 25 von 387

Suche als RSS-Feed

Aktive Filter

KollektionWiley Online Library

KollektionEZB Free E-Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(381)
Mit Volltextzugriff
(373)

Publikationsform

Sprache

Englisch
(387)
Japanisch
(24)

Erscheinungsjahr

n.n

Thema

Science & Technology
(117)
Life Sciences & Biomedicine
(115)
Humans
(99)
Hematology
(93)
Female
(44)
Male
(42)
Oncology
(42)
Middle Aged
(37)
Mutation
(35)
Life Sciences
(33)
Adult
(31)
Aged
(29)
Biological And Medical Sciences
(25)
Hematologic And Hematopoietic Diseases
(25)
Medical Sciences
(25)
Janus Kinase 2 - Genetics
(22)
Patients
(21)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(20)
Janus Kinase 2
(19)
Myelofibrosis
(19)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

From leeches to interferon: should cytoreduction be prescribed for all patients with polycythemia vera?

The renaissance of interferon therapy for the treatment of myeloid malignancies

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients

Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review

Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis

Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project

Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis

Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms

Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib

Aktive Filter

Suchergebnisse filtern